We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Advisory Committee Backs Biosimilars of Humira and Enbrel
FDA Advisory Committee Backs Biosimilars of Humira and Enbrel
An FDA advisory committee recommended FDA approve Amgen’s biosimilar of the AbbVie’s blockbuster drug Humira and Sandoz’s biosimilar of Amgen’s Enbrel.